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Abstract Pancreatic cancer cells are usually resistant to
apoptosis mediated by intrinsic or extrinsic factors. BAG-3
(Bis, CAIR), which was identified as a BAG-1-related protein, is
a novel modulator of cellular anti-apoptotic activity that
functions through its interaction with Bcl-2. In this study we
analyzed BAG-3 expression in human pancreatic cancer tissues
and cell lines. BAG-3 mRNA was expressed at moderate to high
levels in all pancreatic cancer samples, but at low levels in normal
pancreas tissues. In situ hybridization and immunohistochemistry
analysis revealed that BAG-3 was present in the cancer cells
within the pancreatic tumor mass. When BAG-3 mRNA was
analyzed in other gastrointestinal cancers (hepatocellular carci-
noma; esophageal, stomach and colon cancer), no difference was
found from their corresponding normal controls. In pancreatic
cancer cells, BAG-3 mRNA expression levels were strongly
induced after heat stress, but not in response to members of the
tumor necrosis factor (TNF)-K family (TNF-K, TRAIL, FasL).
These findings indicate that in pancreatic cancer, in contrast to
other gastrointestinal malignancies, increased levels of BAG-3
might function to block apoptosis. This characteristic of
pancreatic cancer might contribute to its more aggressive growth
behavior and poor responsiveness to treatment in vivo. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
During the process of malignant transformation, pancreatic
cancer cells acquire resistance to apoptosis through a number
of mechanisms, including p53 and K-ras mutations, aberrant
expression of members of the Bcl-2-related gene family [1^3],
and excessive activation of mitogenic pathways [4]. Pancreatic
cancer cells are also resistant to apoptosis mediated by tumor
necrosis factor (TNF)-K and FasL, and respond only poorly
to TRAIL-mediated apoptosis [5^7]. This resistance, together
with additional molecular alterations, contributes to unre-
sponsiveness towards chemotherapy and/or radiotherapy in
pancreatic cancer.
Intensive research has resulted in the identi¢cation of sev-
eral proteins, which may promote carcinogenesis by inhibiting
apoptosis. These proteins include, among others, members of
the Bcl-2 family, which regulates apoptotic cell death and
consists of several subfamilies, such as the anti-apoptotic
Bcl-2 subfamily (Bcl-2, Bcl-xL and Bcl-W), the pro-apoptotic
Bax subfamily (Bax, Bak and Bok), and the pro-apoptotic
BH3 subfamily (Bad, Bik, Bid, Blk, Hrk, BNIP3 and BimL)
[8,9].
Recent ¢ndings suggest that tumor cell death induced by
chemotherapy and radiotherapy may be mediated by activa-
tion of apoptosis. The fact that pancreatic cancer has an ex-
tremely malignant potential and that it is resistant to most
anti-cancer treatment modalities suggests that mechanisms
are activated that increase the viability of pancreatic cancer
cells. We have previously demonstrated enhanced expression
of the anti-apoptotic gene Bcl-xL in pancreatic cancer and
have shown that its enhanced expression is associated with
shorter patient survival [2]. In line with this observation,
high levels of Bcl-xL protect pancreatic cancer cells from
FasL- and TRAIL-mediated apoptosis [10]. In addition, the
anti-apoptotic gene Bcl-2 is overexpressed in approximately
1/3 of pancreatic cancer samples, yet there is no correlation
between Bcl-2 expression and patient survival [1]. In contrast,
the pro-apoptotic gene Bax was found to be overexpressed in
approximately 2/3 of pancreatic cancers, and enhanced ex-
pression of this molecule correlated with longer survival of
pancreatic cancer patients [1]. Other members of the Bcl-2
family have also been found to be aberrantly expressed in
pancreatic cancer [3,11]. Collectively, these ¢ndings suggest
that deregulation of the expression of members of the Bcl-2
family can enhance the viability of pancreatic cancer cells in
vivo and that this might be one of the reasons why pancreatic
cancers show only limited sensitivity to anti-cancer treat-
ments.
BAG-3 (also known as Bis and CAIR) is a member of the
Bag family of heat shock 70-kDa (Hsp70) chaperone regula-
tors [12]. The BAG-3 protein contains a C-terminal Hsp70-
binding ‘BAG’ domain, together with a WW domain. BAG-3
binds with high a⁄nity to the ATPase domain of Hsc70/
Hsp70, inhibiting its chaperone activity [12]. However,
BAG-3 (Bis) has also been reported to associate with the
anti-apoptotic protein Bcl-2 [13]. Functional analysis revealed
that BAG-3 itself exerts only weak anti-apoptotic activity, but
acts synergistically with Bcl-2 in preventing Bax-induced and
FasL/Fas-mediated apoptosis [13]. The cellular functions are
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poorly understood. One report suggested that BAG-3 (CAIR)
can associate with phospholipase-C following stimulation with
epidermal growth factor (EGF) [12^14].
We have previously shown that another member of the
BAG family, BAG-4 (SODD), is overexpressed in pancreatic
cancer [15]. In view of the resistance of pancreatic cancer to
apoptosis and the likely involvement of the BAG family in
this process, in the present study we investigated the expres-
sion pattern of BAG-3 in diseased and normal human pan-
creatic tissues and analyzed the e¡ects of heat shock and ex-
posure to TNF-K family members on the expression of this
molecule.
2. Materials and methods
2.1. Patients and tissue collection
Normal human tissue samples from the pancreas, liver, esophagus,
stomach and colon were obtained through an organ-donor program
from 20 individuals who were free of any apparent disease. The me-
dian age of the organ donors was 57 years, with a range of 27^73
years. Cancer tissue samples were obtained from 30 pancreatic cancer
patients (11 female and 19 male, median age 65 years) undergoing
pancreatic resection and from six liver, esophageal, stomach, and
colon cancer patients undergoing tumor resection.
Freshly removed tissue samples were immediately ¢xed in para-
formaldehyde solution for 12^24 h and para⁄n-embedded for in
situ hybridization and immunohistochemical staining. Concomitantly,
tissue samples for RNA and protein extraction were immediately snap
frozen in liquid nitrogen in the operating room upon surgical removal
and maintained at 380‡C until use in Northern blot and Western blot
analyses. The Human Subject Committee of the University of Bern
approved all studies.
2.2. Cell culture
Human pancreatic cancer cells were routinely grown in Dulbecco’s
modi¢ed Eagle’s medium (PANC-1, MIA-PaCa-2) or RPMI (T3M4,
ASPC-1 and CAPAN-1) supplemented with 10% heat-inactivated fe-
tal calf serum, 100 U/ml penicillin, 100 Wg/ml streptomycin, and 2 mM
L-glutamine. Cells were maintained at 37‡C in a humid chamber with
5% CO2 and 95% air atmosphere.
2.3. Cytokines and antibodies
Recombinant human TNF-K (RpD Systems GmbH, Wiesbaden-
Nordenstadt, Germany), recombinant human TRAIL (Alexis Corp.,
Lausen, Switzerland) and agonistic monoclonal anti-Fas antibody
(RpD Systems GmbH) were used for induction of apoptosis. The
rabbit polyclonal anti-BAG-3 antibody was raised against a gluta-
thione S-transferase (GST) fusion protein containing 196 amino acids
of the C-terminal portion of BAG-3.
2.4. Probe synthesis for Northern blot analysis and in situ hybridization
A 201-bp fragment of human BAG-3 cDNA was ampli¢ed by RT-
PCR using the following primers: forward: 5P-GAGAGACGGTGT-
CAGGAAGG-3P, reverse: 5P-GTGTGGGGATCTTCTGCATT-3P.
The puri¢ed PCR products were subcloned into the pGEM-T Easy
vector (Promega Biotechnology, Madison, WI, USA) according to the
manufacturer’s instructions. The identity of the cDNA fragments was
con¢rmed by sequence analysis using the dye terminator method (Per-
kin Elmer, Rot Kreuz, Switzerland). A 190-bp fragment of mouse 7S
that cross-hybridizes with human 7S was used to verify equivalent
RNA loading and transfer in Northern blot analysis. For Northern
blot analysis, the probes were radiolabeled with [K-32P]dCTP (Du
Pont International, Regensdorf, Switzerland) using a random prim-
er-labeling system (Roche Diagnostic Ltd., Rotkreuz, Switzerland).
For in situ hybridization, digoxigenin-labeled BAG-3 cRNA sense
and antisense probes were generated using the Ribomax System
(Promega Biotechnology, Madison, WI, USA) and the appropriate
polymerases, as described previously [16,17].
2.5. Northern blot analysis
The procedures used have been described in detail previously
[16,17]. Brie£y, following electrophoresis of total RNA in 1.2% aga-
rose/1.8 M formaldehyde gels, RNA was electrotransferred onto ny-
lon membranes (Gene Screen, Du Pont, Boston, MA, USA) and
cross-linked by UV irradiation. The ¢lters were then pre-hybridized
for 5 h at 42‡C and hybridized for 20 h at 42‡C in the presence of the
radiolabeled cDNA probes for BAG-3 (106 cpm/ml). Blots were then
rinsed twice with 2U SSC at 50‡C and washed twice with 0.2U SSC/
2% sodium dodecyl sulfate (SDS) at 55‡C for 20 min. All blots were
exposed at 380‡C to Kodak XAR-5 ¢lm with Kodak intensifying
screens, and the intensity of the radiographic bands was quanti¢ed
by video image analysis using the Image-Pro plus software (Media
Cybernetics, Silver Spring, MD, USA). To verify equivalent RNA
loading on Northern blot membranes, ¢lters were rehybridized with
the 7S cDNA probe, as reported previously [16,17].
2.6. In situ hybridization
Tissue sections (4 Wm) were depara⁄nized, dehydrated, and incu-
bated in 0.2 M HCl for 20 min. The sections were treated with pro-
teinase K (50 Wg/ml) for 15 min at 37‡C. Following post-¢xation with
4% paraformaldehyde in phosphate-bu¡ered saline (PBS) for 5 min,
the samples were pre-hybridized at 60‡C for 2 h in 50% formamide
(v/v), 4U SSC, 2U Denhardt’s solution and 250 Wg/ml RNA. Hybrid-
ization was performed overnight at 60‡C in 50% (v/v) formamide, 4U
SSC, 2U Denhardt’s solution, 500 Wg/ml RNA and 10% dextran sul-
fate (w/v). The ¢nal concentrations of the digoxigenin-labeled probes
were approximately 0.5 ng/Wl. After hybridization, the sections were
washed and treated with RNase. The samples were then incubated
with an anti-digoxigenin antibody conjugated with alkaline phospha-
tase (1:500). For color reaction, 5-bromo-4-chloro-3-indolyl phos-
phate and nitro-blue-tetrazolium (Sigma, Buchs, Switzerland) were
used. For control experiments, the slides were incubated with RNase
Fig. 1. Northern (A,B) and immunoblot (C) analysis of BAG-3 in
pancreatic tissues. A: Total RNA (20 Wg) isolated from normal and
cancerous pancreatic tissues was subjected to Northern blot analysis
and hybridized with the 32P-labeled BAG-3 cDNA probe. Blots
were subsequently rehybridized with a 7S cDNA probe to verify
equivalent RNA loading. B: Densitometry of the Northern blots.
Relative BAG-3 mRNA expression was calculated as ODBAG-3/
OD7S for each sample, and the fold increase over the mean in the
normal pancreatic tissues was calculated. Horizontal lines represent
the mean values of each group. C: Protein from each sample (40
Wg) was subjected to immunoblot analysis using anti-BAG-3 anti-
bodies, as described in Section 2. Antibody detection was performed
with the enhanced chemoluminescence system.
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or with the corresponding sense probes. Pre-treatment of the slides
with RNase abolished the hybridization signals produced by the anti-
sense probe. Furthermore, incubation with the sense probe failed to
produce speci¢c in situ hybridization signals.
2.7. Immunoblot analysis
Approximately 200 mg of frozen normal and cancer tissues were
pulverized in liquid nitrogen and thawed in an ice-cold suspension
bu¡er (10 mM Tris^HCl, pH 7.6, 100 mM NaCl) containing a pro-
teinase inhibitor cocktail (RpD Systems GmbH, Wiesbaden-Norden-
stadt, Germany). Cultured pancreatic cancer cells (1U106) were
washed in ice-cold PBS, scraped, centrifuged brie£y, and lysed in
1 ml of ice-cold lysis bu¡er (50 mM Tris^HCl, pH 7.5, 150 mM
NaCl, 2 mM EDTA, 1% SDS), supplemented with the Complet-TM
mixture of proteinase inhibitors (Roche Diagnostics, Basel, Switzer-
land). Tissues and cells were homogenized for 5 min and then centri-
fuged (14 000 rpm, 30 min at 4‡C). The supernatants were collected
and assessed for protein concentration with the micro BCA protein
assay (Pierce Chemical Co., Rockford, IL, USA).
Protein from each sample (40 Wg) was diluted in sample bu¡er (250
mM Tris^HCl, 4% SDS, 10% glycerol, 0.006% bromophenol blue and
2% L-mercaptoethanol), boiled for 5 min, cooled on ice for 5 min, and
size-fractionated on 12% SDS^polyacrylamide gels. Gels were trans-
ferred onto nitrocellulose membranes at 100 V for 90 min.
Nitrocellulose membranes were incubated in a blocking solution
containing 5% non-fat milk in TBS-T (20 mM Tris^HCl, 150 mM
NaCl, 0.1% Tween-20), followed by incubation with polyclonal rabbit
anti-BAG-3 antiserum in blocking solution (0.1% v/v) for 1 h at room
temperature. The membranes were then washed with TBS-T and in-
cubated with a horseradish peroxidase-conjugated goat anti-rabbit
IgG (Bio-Rad Laboratories, Hercules, CA, USA, 1:3000 dilution).
Antibody detection was performed with the enhanced chemolumines-
cence immunoblot detection system (Amersham Life Science, Amer-
sham, UK). The intensity of the bands was quanti¢ed by video image
analysis using the Image-Pro plus software.
2.8. Immunohistochemistry
Immunohistochemical analysis was performed with the streptavi-
din^peroxidase technique, as previously reported [16,17]. Brie£y, con-
secutive 3^5 Wm para⁄n-embedded tissue sections were depara⁄nized
and dehydrated. Incubating the slides in methanol containing 0.6%
hydrogen peroxide blocked endogenous peroxidase activity. Then the
sections were incubated for 30 min at room temperature with 10%
normal goat serum prior to 1-h incubation at room temperature
with the BAG-3 antibodies (3.4 ng/Wl) diluted in 10% normal goat
serum. Secondary biotinylated goat anti-rabbit IgG (Kirke-
gaardpPerry Laboratories Inc., Gaithersburg, MD, USA) were
used. Slides were counterstained with Mayer’s hematoxylin. To ensure
speci¢city of the primary antibodies, consecutive tissue sections were
incubated either in the absence of the primary antibody or with a non-
Fig. 2. Localization of BAG-3 mRNA and protein. In situ hybridization (A^C) was carried out with a BAG-3-speci¢c digoxigenin-labeled anti-
sense (A,B) and sense control (C) probe and anti-digoxigenin antibodies conjugated with alkaline phosphatase, as described in Section 2. Immu-
nohistochemistry analysis (D^F) was performed with the streptavidin^peroxidase technique using anti-BAG-3 antibodies, as described in Section
2. Analyses were performed in the normal pancreas (A,D) and pancreatic cancer tissues (B^F).
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immunized rabbit IgG antibody. In these cases no immunostaining
was detected.
2.9. Heat-stress experiments
After exposure to heat stress, BAG-3 mRNA and protein levels
were analyzed by Northern blot analysis and immunoblot analysis.
For Northern blot analysis, three pancreatic cancer cell lines (CA-
PAN-1, PANC-1 and T3M4) were heat-stressed at 45‡C for 10, 30
or 60 min and mRNA was extracted following incubation at 37‡C for
60 min. For immunoblot analysis, three pancreatic cancer cell lines
(CAPAN-1, PANC-1 and T3M4) were heat-stressed at 45‡C for
10 min and protein was extracted following incubation for 0, 1, 3,
6 or 12 h at 37‡C.
2.10. BAG-3 induction experiments
CAPAN-1 cells (5U104) were cultured for 24 h in complete medium
and subsequently treated with TNF-K (10 ng/ml), TRAIL+enhancer
(100 ng/ml, 2 Wg/ml) or agonistic anti-Fas antibody (100 ng/ml) for 0,
1, 3, 6, 24 and 48 h at 37‡C. Cells were harvested and analyzed by
immunoblotting, as described above.
2.11. Statistical analysis
Results are expressed as median and range or mean þ standard de-
viation (S.D.). For statistical analysis the Student’s t-test was used.
Values of P6 0.05 were de¢ned as signi¢cant.
3. Results
3.1. BAG-3 mRNA expression and protein levels in normal and
cancerous pancreatic tissues
Normal pancreatic samples (n = 20) and pancreatic cancer
samples (n = 30) were investigated by Northern blot analysis
(Fig. 1A). The transcript size of BAG-3 mRNA was approx-
imately 2.8 kb. The BAG-3 mRNA transcript was detected at
moderate to high levels in all pancreatic cancer samples, but
at low levels in normal pancreatic tissue samples. Quanti¢ca-
tion of mRNA signals revealed that BAG-3 mRNA levels
were 4.2 þ 0.9-fold increased (P6 0.01) when all cancer sam-
ples were compared with the normal samples (Fig. 1B).
To determine whether BAG-3 protein levels were also ele-
vated in pancreatic cancer, immunoblot analysis was carried
out using four normal and four pancreatic cancer samples.
The pancreatic cancers selected were those that exhibited the
highest mRNA expression levels by Northern blotting. Immu-
noanalysis revealed a single band of approximately 80 kDa, in
accordance with the known size of BAG-3 [12]. The BAG-3
protein was present at higher levels in all pancreatic cancer
samples compared to normal tissues (Fig. 1C). Densitometric
analysis of the autoradiograms indicated that in comparison
with normal pancreatic tissues, there was a 5.4 þ 0.8-fold in-
crease (P6 0.01) of BAG-3 protein levels in pancreatic cancer
tissues.
3.2. Localization of BAG-3 mRNA and protein in the normal
and cancerous pancreas
To assess the exact site of BAG-3 expression in human
pancreatic cancer samples, in situ hybridization and immuno-
histochemistry were carried out next. BAG-3 mRNA signals
were weak to absent in the normal pancreas (Fig. 2A). In
contrast, BAG-3 mRNA signals were intense in the cytoplasm
of cancer cells (Fig. 2B). Similarly, BAG-3 immunoreactivity
was weak to absent in the normal pancreas (Fig. 2D). In
contrast, in pancreatic cancer tissues, strong BAG-3 immuno-
reactivity was present in the cytoplasm of cancer cells within
the pancreatic tumor mass (Fig. 2E,F).
Fig. 3. Northern blot analysis of BAG-3 mRNA in liver, esophagus,
stomach and colon tissues. Total RNA (20 Wg) isolated from the in-
dicated normal and cancerous tissues was subjected to Northern
blot analysis and probed with the 32P-labeled BAG-3 cDNA. Blots
were subsequently rehybridized with the 7S cDNA probe to verify
equivalent RNA loading.
Fig. 4. Northern and immunoblot analysis of BAG-3 in pancreatic
cancer cell lines. A: Total RNA (20 Wg) of ¢ve pancreatic cancer
cell lines was subjected to Northern blot analysis and probed with
the 32P-labeled BAG-3 cDNA. B: Protein samples (40 Wg) from ¢ve
pancreatic cancer cell lines were subjected to immunoblot analysis
using anti-BAG-3 antibodies, as described in Section 2. Antibody
detection was performed with the enhanced chemoluminescence sys-
tem.
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3.3. BAG-3 expression in other normal and cancerous
gastrointestinal organs
Tissue samples of other gastrointestinal cancers (hepatocel-
lular carcinoma, esophageal cancer, stomach cancer and colon
cancer) and the corresponding normal tissue samples were
investigated by Northern blot analysis to determine whether
di¡erences in BAG-3 mRNA expression exist (Fig. 3). Inter-
estingly, in contrast to the results observed in pancreatic can-
cer, BAG-3 mRNA levels in these gastrointestinal cancers
were not obviously di¡erent from levels in the corresponding
normal tissues (Fig. 3). Densitometric quanti¢cation of
mRNA signals revealed that BAG-3 mRNA levels were not
signi¢cantly changed (Ps 0.05) when cancer samples were
compared with the respective normal samples.
3.4. BAG-3 expression in pancreatic cancer cell lines
Next, ¢ve human pancreatic cancer cell lines were investi-
gated by Northern blot and immunoblot analysis. BAG-3
mRNA was detectable in T3M4, ASPC-1 and PANC-1 cells
at high levels, and in CAPAN-1 and MIA-PaCa-2 cells at
moderate levels (Fig. 4A). BAG-3 protein was strongly
present in T3M4 and moderately present in the remaining
pancreatic cancer cell lines (Fig. 4B).
3.5. E¡ect of heat stress on BAG-3 expression
We investigated whether heat stress induces an increase in
BAG-3 levels. To this end, cells were heat-stressed at 45‡C for
various times and RNA was extracted following a 60-min
incubation period at 37‡C. In CAPAN-1 and PANC-1 cells,
maximal induction of BAG-3 mRNA occurred after 10 min of
exposure, whereas longer heat stress of up to 60 min caused
signi¢cantly less induction of BAG-3 mRNA expression. In
contrast, in T3M4 cells, maximal induction of BAG-3 mRNA
occurred after 30 min of exposure (Fig. 5A).
Based on the Northern blot ¢ndings, we investigated
whether BAG-3 mRNA upregulation also leads to an increase
in BAG-3 protein content. To this end, cells were heat-
stressed at 45‡C for 10 min and protein was extracted follow-
ing incubation at 37‡C for various times. The 10-min heat
stress was chosen since all three cell lines exhibited a signi-
¢cant increase in BAG-3 mRNA expression at this time
(Fig. 5A). In CAPAN-1 cells, BAG-3 protein levels in-
creased slowly, with maximal levels observed 6 h after the
10-min heat stress. In PANC-1 cells, BAG-3 protein levels
increased faster, yet maximal levels were also observed 6 h
after the 10-min heat stress. In T3M4 cells, BAG-3 protein
levels increased 1 h after the heat stress and decreased sub-
sequently (Fig. 5B).
3.6. E¡ect of TNF-ligand treatment on BAG-3 expression
BAG-3 protein levels were analyzed by immunoblotting
following treatment with TNF-K, TRAIL or agonistic anti-
Fas antibodies. CAPAN-1 cells were utilized for these experi-
ments since they displayed low-basal BAG-3 mRNA and pro-
tein levels with a strong induction following heat stress (Fig.
5). The levels of BAG-3 expression were not signi¢cantly
changed following exposure to these three TNF ligands.
Thus, there was no signi¢cant di¡erence in BAG-3 levels at
0, 1, 3, 6, 24 and 48 h after treatment with the respective TNF
ligands (Fig. 6).
4. Discussion
Apoptosis, or programmed cell death, is a normal physio-
logic process which occurs during embryonic development, as
well as during maintenance of tissue homeostasis. In the
course of cell division and di¡erentiation, a surplus of cells
is generated, which the normal organism eliminates by the
activation of apoptotic signaling pathways [18]. Deregulation
Fig. 5. E¡ect of heat stress on BAG-3 expression levels in pancreat-
ic cancer cells. A: Cells were heat-stressed at 45‡C for the indicated
time and RNA was extracted following a 60-min incubation at
37‡C. BAG-3 mRNA expression levels were determined by North-
ern blot analysis, as described in Section 2. B: Cells were heat-
stressed at 45‡C for 10 min and protein was extracted following in-
cubation at 37‡C for the indicated time. BAG-3 protein levels were
determined by immunoblot analysis, as described in Section 2.
Fig. 6. E¡ect of TNF-family ligands on BAG-3 expression levels in
CAPAN-1 pancreatic cancer cells. Cells were cultured for 24 h in
complete medium and subsequently treated with 10 ng/ml TNF-K,
100 ng/ml TRAIL (and 2 Wg/ml enhancer), or 100 ng/ml agonistic
anti-Fas antibody (Fas AB) for the indicated time. BAG-3 protein
levels were determined by immunoblot analysis, as described in Sec-
tion 2.
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of apoptosis is commonly observed in cancer cells, and may
play an important role in carcinogenesis [8].
Pancreatic cancer has one of the worst prognosis of all
human malignancies, with an overall 5-year survival rate of
less than 1% when all stages are combined [19,20]. One of the
reasons for the dismal prognosis is the general resistance of
pancreatic cancer cells to apoptosis induced extrinsically by
either chemotherapy or radiotherapy [21^23]. Furthermore,
pancreatic cancer cells are also resistant to intrinsic apoptosis
mediated by members of the TNF-K family, such as FasL [5],
TRAIL [6], and TNF-K [7]. The molecular mechanisms that
enable pancreatic cancer cells to escape apoptosis are cur-
rently not well understood, although a number of possible
mechanisms have been proposed, including deregulated ex-
pression of pro- and anti-apoptotic factors [1^3,11], excessive
activation of mitogenic pathways, and mutations of tumor
suppressor genes and oncogenes [4,24].
In the present study we analyzed the newly identi¢ed anti-
apoptotic factor BAG-3 (Bis, CAIR) in pancreatic tissues. We
now show that BAG-3 mRNA is expressed at moderate to
strong levels in all pancreatic cancer samples, but is absent or
only weakly present in the normal pancreas. In situ hybridi-
zation and immunohistochemistry analyses revealed that
BAG-3 is present in the cancer cells within the pancreatic
tumor mass. In contrast to the results in pancreatic cancer,
BAG-3 mRNA levels in other gastrointestinal cancers were
not obviously di¡erent from levels in the corresponding nor-
mal tissues. The observation of relatively high BAG-3 mRNA
levels in some esophageal and gastric tissue specimens (nor-
mal, as well as cancerous) is interesting and warrants further
investigation.
In addition, we show that in cultured pancreatic cancer cell
lines, BAG-3 expression did not change following exposure to
three TNF ligands, but was strongly induced following expo-
sure to heat stress. Although heat-stress induction is arti¢cial
and usually does not occur in vivo, it elicits a variety of
cytoprotective responses. Therefore, studying the e¡ects of
heat stress reveals the general capacity and the mechanisms
of the exposed cells to avoid apoptosis.
The exact function of BAG-3 in pancreatic cancer is cur-
rently unknown. However, increased BAG-3 expression might
contribute to a resistance to apoptosis via several mecha-
nisms:
1. BAG-3 contains a conserved approximately 45-amino acid
region, termed the BAG domain [12]. The BAG domain
speci¢cally binds and stimulates the ATPase activity of
Hsp70/Hsc70 and modulates the function of these molec-
ular chaperones. The homologous BAG-1 protein, which
interacts with Hsp70/Hsc70, causes a wide variety of cellu-
lar e¡ects, including increased resistance to apoptosis, en-
hanced cell proliferation, tumor cell migration and meta-
stasis [12,25,26]. Interestingly, Hsp70 is commonly
overexpressed in human tumors, and its expression in cer-
tain cancer types correlates with poor prognosis [27,28].
Hsp70 also protects tumor cells from TNF-K cytotoxicity
even in the absence of heat treatment and various other
stresses [28]. Therefore, it can be hypothesized that BAG-3
might also provide cytoprotective functions through its ef-
fects on Hsp70/Hsc70.
2. BAG-3 exhibits sequence similarity to SODD (BAG-4),
which is a recently identi¢ed molecule that is reported to
block spontaneous self association of TNF-K receptors,
and thereby prevent apoptosis and NFUB induction [29].
While there is no experimental evidence that BAG-3 func-
tions to block signaling of TNF-K members at the receptor
level, it is intriguing to speculate that enhanced expression
of BAG-3 could contribute to the observed resistance of
pancreatic cancer cells to members of the TNF-K family,
especially considering that there have been no convincing
molecular explanations for this phenomenon. However,
further research is required to explore this hypothesis.
3. BAG-3 may interact with Bcl-2, and thereby prevent apo-
ptosis. There is experimental evidence that BAG-3 acts syn-
ergistically with Bcl-2 in preventing Bax-induced and Fas/
FasL-mediated apoptosis [13]. In view of the fact that pan-
creatic cancers overexpress Bcl-2 in approximately 1/3 of
the cases, and that these tumors almost uniformly overex-
press BAG-3, it is possible that Bcl-2/BAG-3 interactions
contribute to the apoptosis resistance in at least a subgroup
of pancreatic cancer samples.
4. Recently it has been shown that BAG-3 (CAIR) forms an
epidermal growth factor (EGF)-regulated complex with
Hsp70/Hsc70 and latent phospholipase C-Q, suggesting
that BAG-3 may participate as a multifunctional signaling
protein recruiting Hsp70/Hsc70 to pathways activated by
the EGF receptor tyrosine kinase signaling complex [14]. In
view of the excessive activation of mitogenic pathways of
the EGF family in pancreatic cancer [4], it is possible that
the increased BAG-3 levels in pancreatic cancers also con-
tribute to the activation of mitogenic pathways in this dis-
ease, and thereby enhance the growth advantage of pan-
creatic cancer cells in vivo.
In conclusion, the precise function of BAG-3 in human
malignancies is unknown, and it is currently not evident
why enhanced BAG-3 mRNA levels are only observed in
pancreatic cancer, but not in other gastrointestinal malignan-
cies. While further studies are required to address these ques-
tions, the ¢ndings reported here provide preliminary evidence
that BAG-3 plays a role in the pathogenesis or progression of
pancreatic cancer.
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